Abstract
INTRODUCTION 53
Neuropeptide S (NPS) is localized to the brainstem and gastrointestinal tract. NPS activates 54 the G protein-coupled receptor NPSR1 (also named GPR154) and activates adenylate cyclase 55 to increase cAMP (16). NPS is regarded as an excitatory neurotransmitter and is involved in 56 stress responses with regulation of arousal, wakefulness and anxiety in mammals (1, 13) . The 57 presence of an Asn-Gly (NG) sequence is a defining feature of a phylogenetically ancient 58 family of neuropeptides called "NG peptides" (4). Rodent and human NPS possesses this NG 59 sequence (17) . 60 NPS and NPSR1 exist in gastrointestinal mucosal epithelial cells (3, 9, 20 ). An NPSR1 61 polymorphism was reported along with higher mucosal epithelial immunoreactivity of NPSR1 62 in inflammatory bowel disease (IBD) with expression in leukocytes (3). Multiple NPSR1 63 AJP GL W.S.W. Saudi, et al 7 positioned at the same level as the inlet tubing. An upward deflection of at least 2 mm Hg 153 above baseline was defined as a motor response. Changes in luminal pressure were recorded 154 via a digitizer on a computer using PowerLab ® and the software Labchart7 ® (ADInstruments 155
Ltd. Hastings, East Sussex, UK). Intestinal motility was assessed as the pressure-activity 156 curve over baseline (AUC) in 10-min intervals. This "motility index" was expressed as the 157 mean AUC/10 min for any specified period. 158
To study mucosal permeability 51 Cr-EDTA was simultaneously administered IV as a 159 bolus of ~75 µCi followed by continuous infusion at a rate of ~50 µCi/h for 30-60 min to 160 permit equilibration in the tissue. Two blood samples (~0.3 ml each) were drawn during the 161 experiment. The first was collected 10 min before starting, the second after ending the 162 experiment. The blood volume loss was compensated for by injection of a 0.3 ml 7% BSA 163 solution. After centrifugation of samples, 50 µl plasma was removed for measurements of 164 51 Cr-EDTA. The duodenal segment was perfused with saline at a rate of ~0.4 ml/min and the 165 perfusate collected in 10-min samples. The luminal perfusate and plasma were then analyzed 166 for 51 Cr-EDTA. Quantification was done using a gamma counter (Compugamma 1282 CS,  167 Pharmacia, Uppsala, Sweden). A linear regression analysis of the plasma samples was made 168 to obtain a corresponding plasma value for each perfusate sample. The clearance of 51 Cr-169
EDTA from blood-to-lumen was calculated as described previously (5, 18) and expressed as 170 ml/min·100 g at 10-min intervals. 171
Control experiments were performed by measuring basal duodenal motility and 172 mucosal permeability simultaneously for 150 min with saline perfusion of the duodenal 173 segment (n = 9). In a parallel group animals were challenged with NPS. The experimental 174 protocol was the same as under control conditions with addition of NPS administered IV after 175 a 30-min baseline period either as bolus injections at 30 min with 0.5 nmol/kg and at 70 min 176 with 5.0 nmol/kg (n =10) after onset of experiment, or as NPS infusions IV at doses 8, 83 and In studies of colonic motility, baseline studies during 30 min were carried out with an 179 infusion of bethanechol 2.5 mmol/kg·min to induce motility for a total period of 60 min (n = 180 5). In a parallel group a continuous infusion of NPS at 833 pmol/kg·min IV was added at 30 181 min and motility examined for another 30 min (n = 5). 182
In a separate set of experiments, NO dependency of the NPS effects on duodenal 183 motility and permeability was examined. Similar to control experiments with saline, L-NAME 184 was added as a 3 mg/kg IV bolus dose followed by continuous infusion 4 μg/h for a baseline 185 period of 30 min and throughout the experiments. One group was pre-treated with L-NAME 186 alone (n = 6) and a parallel group with added challenge of NPS (n = 9) at doses of 8, 83 and 187 833 pmol/kg·min IV for a total period of 120 min. 188
Additional experiments were carried out to study inflammatory properties of NPS. (1:1000, cat# ab92424, Cambridge, UK) and rabbit polyclonal against neuronal NOS (nNOS) 223 from Santa Cruz Biotechnology Inc (1:400, NOS1, cat# sc-648, Dallas, TX, USA). Neuron-224 specific staining with this nNOS primary Ab was confirmed using rabbit monoclonal primary 225
Ab against neuron-specific enolase from Cell Signaling Technology® (Beverly, MA, USA) 226
(1:1000, clone D20H2, cat# 8171). Double staining was done using HRP-DAB and AP-Fast 227
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Red simultaneously on same sections. 228
229

Plasma concentrations of NPS 230
Adult subjects were fasted at least 6 h. In healthy volunteers, plasma was prepared from blood 231 collected immediately before and 30, 60 and 180 min after a mixed meal (n = 5). This was 232 compared to plasma from a biobank of active IBD cases (n = 14) of which lipopolysaccharide 233 and C-reactive protein were elevated relative to healthy controls. Active IBD was defined as 234 partial Mayo score ≥6 for ulcerative colitis or Harvey-Bradshaw index ≥6 for Crohn's 235 disease. SigmaFAST protease inhibitor was added to blood samples to mitigate degradation of 236 NPS. A commercial ELISA kit was used to assay NPS (cat# EZHFGF21-19K Millipore, 237
Billerica, MA, USA) according to product insert. The detection limit was 18 pM. Intra-assay 238 coefficient of variation was 3.9%. Spike recovery experiments did not reveal any marked 239 degradation. 240
241
Organ bath motility studies 242
Excised tissue was placed in ice-cold Krebs solution (mM: 121.5 NaCl, 2.5 CaCl 2 , 1.2 243 KH 2 PO 4 , 4.7 KCl, 1.2 MgSO 4 , 25 NaHCO 3 , 5.6 D-glucose, equilibrated with 5% CO 2 and 244 95% O 2 ). The mucosa was removed. Strips were cut (2-3 mm wide, 12-14 mm long) along the 245 circular axis, and mounted between two platinum ring electrodes in organ bath chambers (5 246 ml, Panlab, Barcelona, Spain) containing Krebs solution, continuously bubbled with 5% CO 2 247 and 95% O 2 , maintained at 37 °C and pH 7.4. Tension was monitored using isometric force 248 transducers (MLT0201, PanLab). Data acquisition was performed using Powerlab hardware 249 and LabChart 7 software (ADInstruments, Oxford, UK). The tissues were equilibrated to a 2 g 250 tension baseline for at least 60 min with the medium replaced every 15 min. After 251 equilibration, the muscle strips were stimulated with bethanechol 10 µM (EC 50 8 min to establish a baseline. These contractions prior to experimental treatments were 253 defined as 100% in normalized datasets. The effect of NPS 1-1000 nM (Bachem AG) was 254 studied on smooth muscle strips pretreated with bethanechol (n = 6). To test for prejunctional 255 effects, tissue contractions were evoked by electrical field stimulation (EFS) using biphasic 256 square wave pulses (10 Hz, 50 V, 0.6 ms) with a Grass S88 stimulator (Grass Technologies, 257
Astro-Med Inc., West Warwick, RI, USA) (n = 6). NPS was added to the muscle strip 258 preparations about 30 seconds before EFS. The response to NPS was also tested in the 259 presence of tetrodotoxin (TTX) 1 μM (n = 6), a voltage-dependent Na + -channel blocker, and 260 L-NAME 1 μM, a non-selective NOS inhibitor (n = 6). Wilcoxon signed rank test was used to evaluate effects of NPS on the response to EFS as well 278 as effects of TTX and L-NAME on the response to NPS. P < 0.05 was considered statistically 279 significant. 280
281
RESULTS
282
During administration of NPS into conscious or anesthetized animals, no adverse 283 events were observed regarding appearance, blood circulation, arterial blood pressure or 284 breathing. 285
286
Migrating myoelectric complex 287
The MMC of small intestine in conscious rats was studied with IV infusions of NPS. 288 NPS at low doses 100-1000 pmol/kg·min caused irregular spiking (P < 0.05), whereas higher 289 doses exceeding 1000 pmol/kg·min dampened the myoelectric activity and prolonged the 290 MMC cycle length and phase III duration in a dose-dependent manner (P < 0.01). Table 1 . 293 294
Intestinal motility and mucosal permeability 295
Under baseline conditions, the duodenal motility index for the entire experiment was 296 stable at ~407 ± 27 AUC/10 min (Figures 2A and 2C ) and mucosal paracellular permeability 297 Figure 2C ) and diminished reduction in permeability ( Figure 2D , P < 0.01) in a 303 dose-dependent fashion. 304
Because NO is known to reduce motility and increase mucosal permeability, both of 305 which inhibited by the NOS inhibitor L-NAME (7), dependency of the NPS effects on NOS 306 signaling was studied. Pretreatment with L-NAME, 3 mg/kg loading dose plus 4 μg/min 307 continuous infusion, disinhibited duodenal motility ( Figure 3A ) and inhibited the net 308 reduction of paracellular permeability induced by NPS ( Figure 3B) . 309
310
To characterize the motility effects of NPS on the colon, we investigated colonic 311 motility in vivo in the rat. Under baseline conditions with saline infusion, no spontaneous 312 motility was observed. Therefore, a slow continuous IV infusion of bethanechol 2.5 313 mmol/kg·min was used to induce stable and long-lasting motility. Against this background 314 addition of NPS 833 pmol/kg·min IV inhibited colonic motility (P < 0.01, Figure 4) . In all 315 anesthetized animals, mean arterial blood pressure and body temperature were stable 316 throughout experiments at ~111 mm Hg and ~37-38 ºC, respectively. 317 318
Immunostaining for NPS, NPSR1 and nNOS 319
Immunostaining of human gastric corpus, jejunum, ileum and colon showed strong 320 NPS and NPSR1 (C-terminal) immunoreactivity, however with no specific predominance for 321 any specific organ. In different parts of the gastrointestinal tract, NPSR1 and NPS both 322 localized at myenteric plexus ( Figure 5A and 5B). The strongest NPSR1 staining occurred at 323 neurons within the myenteric plexus. No staining occurred at smooth muscle cells. Double 324 staining verified that NPSR1 resides within neurons and co-localize with nNOS ( Figure 6A) . 325 Double staining confirmed that NPSR1 and NPS reside in different neurons, speaking in favor 326 of a neurocrine function ( Figure 6B ). Neuron-specific nNOS expression (and by inference,
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NPSR1) was confirmed using neuron-specific enolase Ab (data not shown). However, a few 328 cells stained differentially for either NPSR1 or nNOS. 329
330
NPS in human plasma 331
In both healthy and subjects with active IBD, plasma NPS was at or below the 18 pM 332 assay detection limit with no indication of higher levels in active IBD or increased levels with 333 a mixed meal. Standard samples gave expected results and spike recovery pre-tests in plasma 334 did not reveal significant losses. This placed NPS concentrations under all tested conditions 335 no higher than ~10 times below the 300 pmol/L K d for binding to the NPSR1 (16, 21). 336 337
Expression of inflammatory markers 338
The expression of inflammatory markers was analyzed after NPS infusion 4000 339 pmol/kg· min for 60 min the rat multiplex analysis showed an increased expression of IL-1β 340 and CXCL1 in NPS-treated tissue compared with saline-treated animals (P = 0.02 and P = 341 0.04), respectively (Fig. 7) . 342
343
NPS effects on gastrointestinal muscle strips 344
In the organ bath, NPS 1-1000 nM had no effect on unstimulated gastric corpus 345 muscle strips or pre-contracted with bethanechol 10 µM (n = 6; data not shown). In small 346 intestinal muscle strips, basal spontaneous contractions were modestly reduced by NPS (Fig  347   8) . In order to see clear responses to NPS contractions were stimulated with bethanechol or 348 EFS. NPS 1-1000 nM caused dose-dependent reduction of the bethanechol-induced 349 contractions and reached statistical significance at and above 10 nM of NPS ( Figure 9A , n = 350 6; P < 0.05). In colonic muscle strips, NPS 1-1000 nM also inhibited bethanechol-induced 351 contractions. This effect was however sporadic, so dose-dependency could not be accurately
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quantified (n = 6; data not shown). Similar to the in vivo rat experiments, NPS had no effect 353 on small intestine pre-contracted with L-NAME (n = 6) ( Figure 9B) . Furthermore, the 354 inhibitory effect of NPS on motility was abolished in human small intestine by pre-treatment 355 with TTX (n = 6) ( Figure 9C , P < 0.01). Submaximal EFS-induced contractions of colonic 356 muscle strips were dampened to ~61 ± 7% of reference EFS by addition of NPS 1 nM (n = 6) 357 ( Figure 9D , P < 0.01), which displayed recovery to 81 ± 9% of control within 10 min after 358 removing NPS. 359
360
DISCUSSION 361
Disturbed neuroendocrine regulation of gastrointestinal functions is hypothesized to be 362 a factor in the manifestation of functional gastrointestinal disorders and inflammatory bowel 363 disease. In this study, we demonstrated that NPS inhibits small intestinal and colonic motility 364 along with an early inflammatory response. In rats, small and large intestinal motility as well 365 as the pattern and frequency of the MMC were inhibited by NPS in tandem with higher 366 mucosal paracellular permeability. Furthermore, mechanistic studies showed the NPS effects 367 on motility and permeability to be abolished by L-NAME pretreatment, suggesting NO 368 dependency. To this end TTX also inhibited the NPS-induced effects, which is in line with 369 these findings and with a neuronal mechanism of NPS. Taken together with our histological 370 findings of NPS being localized to myenteric neuronal structures in the gut and co-existence 371 with nNOS further support this data. NPS has in many instances been referred to as an 372 excitatory transmitter. The fact that NPS has inhibitory actions in the gut may be explained by 373 an excitatory effect on prejunctional inhibitory neurons in the myenteric plexus. 374 NPS increases cAMP as second messenger. more prone to dysmotility and increased mucosal permeability. 378
The relevance of our animal studies to human conditions was examined using human 379 gastrointestinal muscle strips. In small intestine muscle strips pre-contracted with 380 bethanechol, NPS at concentrations close to the nanomolar range of receptor binding (21) Continuous NPS infusion IV (n = 10) also induced marked and dose-dependent decrease in 558 duodenal motility compared to saline controls (n = 9). Panel D) The net permeability decrease 559 was also reduced by continuous NPS infusion (n = 10) compared to controls (n = 10). # and 560 ## indicate significant (P < 0.05 and P < 0.01) decreases compared with baseline (0-30 min) 561 in the same group. * and ** indicate significant (P < 0.05 and P < 0.01) differences 562 between groups. 563 564 reduced to 61 ± 7% by addition of NPS at 1 nM (n = 6), which recovered to 81 ± 9% within 604 10 min after removal of NPS. In all experiments, recovery was seen after chamber washout. # 605 and ## indicate significant (P < 0.05 and P < 0.01) differences from baseline. * and ** 606 indicate significant (P < 0.05 and P < 0.01) differences between groups. 
